Log in to save to my catalogue

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-ter...

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-ter...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4895174

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV

About this item

Full title

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV

Publisher

London: Nature Publishing Group UK

Journal title

Leukemia, 2016-06, Vol.30 (6), p.1255-1262

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Treatment of chronic myeloid leukemia (CML) has been profoundly improved by the introduction of tyrosine kinase inhibitors (TKIs). Long-term survival with imatinib is excellent with a 8-year survival rate of ∼88%. Long-term toxicity of TKI treatment, especially carcinogenicity, has become a concern. We analyzed data of the CML study IV for the deve...

Alternative Titles

Full title

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4895174

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4895174

Other Identifiers

ISSN

0887-6924

E-ISSN

1476-5551

DOI

10.1038/leu.2016.20

How to access this item